Young By Choice Editorial Team | June 18, 2025
Longevity Science: Major Breakthroughs
1. Klotho Protein Therapy: A Leap in Anti-Aging
Klotho Neurosciences announced pre-clinical results showing that boosting the secreted Klotho (s-KL) protein in mice extends lifespan by 15–20% and improves muscle, bone, and cognitive health. The company has secured global patents and is targeting neurodegenerative diseases like ALS, Alzheimer’s, and Parkinson’s123.
The therapy works by delivering the s-KL gene via viral vectors, with future plans to develop direct protein delivery methods for humans24.
These findings position Klotho-based interventions as one of the most promising avenues for both lifespan and healthspan extension123.
2. NAD+ Supplementation Shows Human Benefits
A landmark clinical trial using nicotinamide riboside (NR), a precursor to NAD+, demonstrated improved cardiovascular health, reduced skin ulcers, and better kidney function in patients with Werner syndrome, a model for accelerated aging56.
Research confirms that boosting NAD+ in cells from patients with premature aging syndromes decreases cellular senescence and improves mitochondrial function, reinforcing the therapeutic potential of NAD+ metabolism in age-related diseases65.
3. Precision Longevity Medicine & Environment
Recent studies highlight that environmental factors account for 17% of mortality variation, compared to genetics’ 2%, emphasizing the importance of exposome-focused interventions and lifestyle modifications for longevity7.
Multiple human clinical trials are underway, including the TAME (Targeting Aging with Metformin) trial and investigations into APJ agonists and AMPK activators, all aiming to address fundamental aging mechanisms7.
Biohacking: Market Trends & Innovations
1. Explosive Growth in Biohacking and Wearables
The global biohacking market is projected to surge from $24.5 billion in 2024 to $111.3 billion by 2034, driven by preventive healthcare and the adoption of advanced wearables8910.
Biohacking wearables—such as smartwatches, fitness trackers, and implantable devices—are expected to reach $67.08 billion by 2034, with demand fueled by real-time biometric data and personalized health optimization910.
Leading companies include Neuralink, Oura Health, WHOOP, Cyborg Nest, and Muse, all investing heavily in next-gen devices and AI-driven health platforms89.
ADVERTISEMENT
2. Biohacking Practices and Regulation
Biohacking now spans from mainstream wearables and nootropics to more experimental practices like gene editing and implantable tech1110.
Regulatory landscapes are evolving: while some countries require licenses for invasive biohacks, the field remains largely self-regulated, with ethical and safety considerations under active debate11.
Other Noteworthy Research
Senolytics: New studies show that the senolytic drug ABT-263 can rejuvenate aged skin and reduce cancer risk after radiation, indicating potential for broader anti-aging applications12.
Epigenetic Aging: Research in primates shows that biological (epigenetic) age can diverge from chronological age, offering new biomarkers for longevity interventions12.
Telomere Research: Genetically engineered mice with human-like telomeres have been developed, providing a more accurate model for studying cellular aging and testing anti-aging therapies13.
Quick Takeaways
Klotho and NAD+ therapies are at the forefront of translational longevity research, with promising results in both animal and early human studies235.
Biohacking is mainstreaming, with wearables and personalized interventions leading market growth, but regulatory and ethical frameworks are still catching up8911.
Precision medicine and environmental interventions are gaining traction, shifting the focus from disease treatment to proactive healthspan extension7.
Stay tuned for tomorrow’s briefing on the latest developments in longevity and biohacking.
